Advisory Board - Overview

The Clinical Advisory Boards has been established to support Alchemia as it builds on its foundations as a forward thinking Australian biopharmaceutical company. The Board supports the Oncology management and teams through their experience and vision and provide critical input into the Company's focus across these areas.

Clinical Advisory Board

Alchemia's Clinical Advisory Board (CAB) consists of key opinion leaders with significant research and clinical experience in oncology. Input from these thought leaders will maximize the company's ability to deliver results that are clinically and commercially significant.
CAB is chaired by Dr Peter Gibbs, who has been the Principal Investigator for the successful Phase I and Phase II HA-irinotecan trials run in Australia. CAB provides advice and guidance on trial design and general oncology

Ludwig Institute, Royal Melbourne Hospital and Western Hospital, Australia.

Dr. Peter Gibbs is a physician-scientist with colorectal cancer (CRC) expertise and lead research across the spectrum from CRC prevention and screening to optimizing the treatment of advanced disease. He has supported a broad range of translational research endeavors and has more than 10 years of comprehensive treatment and outcome data for consecutive patients with CRC across five clinical centers. His international collaborations include the Bert Vogelstein group at the Ludwig Center at Johns Hopkins, with which Associate Professor Gibbs is exploring the utility of circulating tumor DNA for CRC screening as a marker of residual disease in the adjuvant setting and to guide treatment of patients with advanced disease. Associate Professor Gibbs is a lead investigator for the ASPREE study, randomizing 19,000 elderly patients to five years of low-dose aspirin versus placebo. Largely funded by the NIH ($50 million) this study seeks to define the role of aspirin as a cancer chemopreventive.  He is also the lead investigator for multiple phase III clinical trials, including selective internal radiation therapy in the first line treatment of patients with colorectal cancer liver metastases, and studies of delivering irinotecan chemotherapy with hyaluronic acid with potential for both survival and toxicity benefits. Dr. Gibbs also leads an industry-sponsored registry collecting data on 2,500 consecutive patients with newly diagnosed metastatic colorectal cancer at 20 Australian, which is being used to study variations in care and outcomes and to further inform optimal care of patients with advanced CRC. 

Memorial Sloan-Kettering Cancer Centre, USA.

Dr. Len Saltz has served on the faculty of Memorial Sloan Kettering since 1989, having treated thousands of people with both common and rare gastrointestinal cancers. He has particular expertise in managing cancers of the colon and rectum, as well as rare tumors of the digestive tract, such as carcinoid and pancreatic neuroendocrine tumors; and other digestive tract cancers, such as liver, pancreas, stomach, and esophageal cancers. Dr. Saltz is currently Chief of the Gastrointestinal Medical Oncology Service, Chair of the hospital’s Pharmacy and Therapeutics Committee, and co-leader of the Colorectal Disease Management Team. Dr. Saltz is also a Professor of Medicine at Weill Cornell Medical College. Nationally, he serves on the National Cancer Institute (NCI) Rectal and Anal Cancer Task Force and is co-leader of the Alliance NCI Cooperative Research Group efforts in colon and rectal cancers. He also serves on three National Comprehensive Cancer Network (NCCN) guidelines committees. Dr. Saltz has authored or co-authored more than 150 peer-reviewed journal articles on the development of new treatments for colorectal and other gastrointestinal cancers. He has also written numerous books, book chapters, monographs, and reviews on current and future treatment strategies for these diseases. Over the years, he has received numerous teaching and research awards, as well as recognition for his work from such organizations as the American Cancer Society (Career Development Award) and Gilda’s Club (Advancement of Cancer Medicine Award).

Alchemia Oncology Pty Ltd and Monash University Australia.

Dr. Tracey Brown joined Alchemia in 2006 as a result of the successful acquisition of Meditech Research. She is responsible for the evaluation of lead compounds from both Alchemia’s discovery and HyACT programs, where her primary role is to take the potential therapeutics into both non-clinical and clinical development. Over the last 33 years while working in several cancer and commercial institutes in both USA and Australia, Dr.Brown gained international experience in managing both academic and commercial drug development teams. Through this experience she contributed to the commercial development of drugs and medical devices which have primarily focused on the therapeutic applications of carbohydrates. This drug development experience culminated in the invention of the HyACT platform and the development of three drugs from conception through clinical evaluation. Dr. Brown has authored numerous research articles, book chapters and reviews on the role of carbohydrates in cancer and other therapeutic applications. In addition, she has received numerous research awards, as well as recognition for her work from such organizations as the International Matrix Biology Institute.

University Hospital Gathuisberg, Belgium.

Professor Eric van Cutsem trained in internal medicine and gastroenterology in Leuven and specialised later in GI oncology in Leuven, Belgium. He currently serves as Professor of Internal Medicine at the University of Leuven and is head of the Digestive Oncology department at the University Hospital Gasthuisberg in Leuven. Additionally, Dr. van Cutsem is a board member of Leuven Cancer Institute and of the Department of Oncology at the University of Leuven. He obtained his medical degrees at the University of Leuven. He has published more than 300 peer-reviewed articles in prestigious journals, including the New England Journal Medicine, the Journal of Clinical Oncology, Lancet, Lancet Oncology, JAMA, and the Annals of Oncology and European Journal of Cancer. He is co-editor of the reference textbook on gastrointestinal cancer, Principles and Practice of Gastrointestinal Oncology. Dr. van Cutsem has been involved as a member of the Scientific Program Committee and the educational committee of ASCO, ASCO-GI cancers symposium, ESMO and ECCO. He is also a member of the ESMO faculty and joined the ESMO executive board in 2011. He served as secretary of the European Organisation for Research and Treatment of Cancer – Gastrointestinal Cancer (EORTC-GI) group from January 2000 to 2003 and was chair of the EORTC-GI group from 2003 to 2007. He has also served as Chairman of PETACC (Pan-European Trials on Adjuvant Colon Cancer) since 2008 and has been a board member of the EORTC since 2009. Dr. van Cutsem is currently the President of European Society of Digestive Oncology (ESDO) and is Co-chairman of the European NeuroEndocrine Tumour Society (ENETS) registry. He is also Chairman of the governmental colon cancer prevention task force in Flanders, Belgium and is President of BGDO (Belgian Group Digestive Oncology) and FAPA (Familial Adenomatous Polyposis Association). He is the founder and Chairman of the Scientific Committee of the World Congress on Gastrointestinal Cancer in Barcelona.

Royal Marsden Hospital, UK.

Dr. Ian Chau holds the position of Consultant Medical Oncologist within the Gastrointestinal and Lymphoma Units. He is also a Senior Lecturer at the Institute of Cancer Research. He received his medical degree from the United Medical and Dental Schools of Guy’s and St. Thomas’ Hospital, University of London, before undergoing medical oncology specialist training and completing his clinical research fellowship at the Royal Marsden Hospital. He is the principal investigator of multiple phase I, II and III clinical trials evaluating novel treatment strategies and agents in various cancer signalling pathways and currently serves on committees for the UK National Cancer Research Institute (NCRI) Colorectal Cancer and Pancreatic Cancer Clinical Study Groups, as well as the American Society of Clinical Oncology (ASCO) Scientific Program Committee. He is also on the trial management groups of the UK NCRI phase III gastrointestinal cancer and lymphoma trials and International Advisory Panel for the Cancer Research UK Clinical Trials Awards & Advisory Committee. Dr. Chau is the recipient of merit awards from ASCO Gastrointestinal Cancer Symposium, as well as the Royal Society of Medicine Section of Oncology Clinical Prize. He has also earned fellowships from the European School of Oncology and ASCO/AACR/FECS Clinical Cancer Research Workshop. He has served on international drug development advisory boards and has peer review publications in the New England Journal of Medicine, the Journal of Clinical Oncology, and other leading oncology / biomedical journals.